Lipocine Inc. held its annual general meeting of shareholders on June 4, 2025. During the meeting, shareholders approved the amendment to reduce the number of authorized shares of Common Stock from 200,000,000 to 75,000,000. The election of six directors was confirmed. The appointment of Tanner LLC as the independent registered public accountants for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.